Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents.
Seko Y, Moriguchi M, Takahashi A, Yamaguchi K, Umemura A, Okuda K, Kataoka S, Unozawa H, Kobayashi K, Ogasawara S, Sato R, Tsuchiya S, Watanabe S, Morimoto N, Iwai K, Aramaki T, Kato N, Itoh Y. Seko Y, et al. Among authors: umemura a. J Gastroenterol. 2022 Feb;57(2):90-98. doi: 10.1007/s00535-021-01837-5. Epub 2022 Jan 15. J Gastroenterol. 2022. PMID: 35031857
High expression of p300 in HCC predicts shortened overall survival in association with enhanced epithelial mesenchymal transition of HCC cells.
Yokomizo C, Yamaguchi K, Itoh Y, Nishimura T, Umemura A, Minami M, Yasui K, Mitsuyoshi H, Fujii H, Tochiki N, Nakajima T, Okanoue T, Yoshikawa T. Yokomizo C, et al. Among authors: umemura a. Cancer Lett. 2011 Nov 28;310(2):140-7. doi: 10.1016/j.canlet.2011.06.030. Epub 2011 Jul 1. Cancer Lett. 2011. PMID: 21764211
Hepatic steatosis in chronic hepatitis C patients infected with genotype 2 is associated with insulin resistance, hepatic fibrosis and affects cumulative positivity of serum hepatitis C virus RNA in peginterferon and ribavirin combination therapy.
Itoh Y, Nishimura T, Yamaguchi K, Yokomizo C, Fujii H, Minami M, Nagao Y, Sumida Y, Hashimoto H, Umemura A, Shima T, Okanoue T, Yoshikawa T. Itoh Y, et al. Among authors: umemura a. Hepatol Res. 2011 Dec;41(12):1145-52. doi: 10.1111/j.1872-034X.2011.00886.x. Epub 2011 Sep 26. Hepatol Res. 2011. PMID: 21951359
Treatment extension may benefit female genotype 1 chronic hepatitis C patients with complete early virological response to peginterferon-alpha-2b and ribavirin combination therapy.
Nishimura T, Yamaguchi K, Hashimoto H, Niimi T, Yokomizo C, Fujii H, Minami M, Sakamoto M, Ohnish N, Nagao Y, Okita M, Umemura A, Shima T, Okanoue T, Itoh Y. Nishimura T, et al. Among authors: umemura a. Hepatol Res. 2012 Oct;42(10):966-73. doi: 10.1111/j.1872-034X.2012.01016.x. Epub 2012 May 1. Hepatol Res. 2012. PMID: 22548706
Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus.
Shima T, Uto H, Ueki K, Takamura T, Kohgo Y, Kawata S, Yasui K, Park H, Nakamura N, Nakatou T, Tanaka N, Umemura A, Mizuno M, Tanaka J, Okanoue T. Shima T, et al. Among authors: umemura a. J Gastroenterol. 2013 Apr;48(4):515-25. doi: 10.1007/s00535-012-0653-5. Epub 2012 Aug 22. J Gastroenterol. 2013. PMID: 22911170
Prediction of a favorable clinical course in hepatitis C virus carriers with persistently normal serum alanine aminotransferase levels: A long-term follow-up study.
Nishimura T, Yamaguchi K, Fujii H, Okada Y, Yokomizo C, Niimi T, Sumida Y, Yasui K, Mitsuyoshi H, Minami M, Umemura A, Shima T, Okanoue T, Itoh Y. Nishimura T, et al. Among authors: umemura a. Hepatol Res. 2013 May;43(5):557-62. doi: 10.1111/j.1872-034X.2012.01091.x. Epub 2012 Sep 14. Hepatol Res. 2013. PMID: 22978477
310 results